ATE459652T1 - Verfahren zur herstellung von antikörpern - Google Patents

Verfahren zur herstellung von antikörpern

Info

Publication number
ATE459652T1
ATE459652T1 AT04734554T AT04734554T ATE459652T1 AT E459652 T1 ATE459652 T1 AT E459652T1 AT 04734554 T AT04734554 T AT 04734554T AT 04734554 T AT04734554 T AT 04734554T AT E459652 T1 ATE459652 T1 AT E459652T1
Authority
AT
Austria
Prior art keywords
cells
antibody
producing antibodies
culturing
captured
Prior art date
Application number
AT04734554T
Other languages
English (en)
Inventor
Alastair David Griffiths Lawson
Daniel John Lightwood
Original Assignee
Ucb Pharma Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ucb Pharma Sa filed Critical Ucb Pharma Sa
Application granted granted Critical
Publication of ATE459652T1 publication Critical patent/ATE459652T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
AT04734554T 2003-05-30 2004-05-24 Verfahren zur herstellung von antikörpern ATE459652T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0312481.5A GB0312481D0 (en) 2003-05-30 2003-05-30 Antibodies
PCT/GB2004/002226 WO2004106377A1 (en) 2003-05-30 2004-05-24 Methods for producing antibodies

Publications (1)

Publication Number Publication Date
ATE459652T1 true ATE459652T1 (de) 2010-03-15

Family

ID=9959074

Family Applications (1)

Application Number Title Priority Date Filing Date
AT04734554T ATE459652T1 (de) 2003-05-30 2004-05-24 Verfahren zur herstellung von antikörpern

Country Status (10)

Country Link
US (1) US7790414B2 (de)
EP (1) EP1633787B1 (de)
JP (1) JP4624357B2 (de)
AT (1) ATE459652T1 (de)
AU (1) AU2004242823A1 (de)
CA (1) CA2526546A1 (de)
DE (1) DE602004025805D1 (de)
ES (1) ES2341544T3 (de)
GB (1) GB0312481D0 (de)
WO (1) WO2004106377A1 (de)

Families Citing this family (174)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0425569D0 (en) 2004-11-19 2004-12-22 Celltech R&D Ltd Biological products
WO2006081139A2 (en) * 2005-01-26 2006-08-03 Abgenix, Inc. Antibodies against interleukin-1 beta
GB0506912D0 (en) 2005-04-05 2005-05-11 Celltech R&D Ltd Biological products
ATE546160T1 (de) 2005-09-14 2012-03-15 Ucb Pharma Sa Antikörper-kammpolymer-konjugat
CA2632628C (en) 2005-12-09 2016-01-19 Ucb Pharma S.A. Antibody molecules having specificity for human il-6
PL2481753T3 (pl) * 2005-12-13 2018-09-28 Eli Lilly And Company Przeciwciała anty-IL-17
US7910703B2 (en) 2006-03-10 2011-03-22 Zymogenetics, Inc. Antagonists to IL-17A, IL-17F, and IL-23P19 and methods of use
EP2021463B1 (de) * 2006-05-19 2016-11-23 Alder Biopharmaceuticals, Inc. Anbauverfahren zum erhalten einer klonpopulation von antigenspezifischen b-zellen
GB0612928D0 (en) * 2006-06-29 2006-08-09 Ucb Sa Biological products
GB0613209D0 (en) 2006-07-03 2006-08-09 Ucb Sa Methods
GB0614780D0 (en) 2006-07-25 2006-09-06 Ucb Sa Biological products
EP2046835B1 (de) 2006-08-11 2011-10-26 Schering Corporation Antikörper gegen il-17a
GB0619291D0 (en) 2006-09-29 2006-11-08 Ucb Sa Altered antibodies
GB0620729D0 (en) 2006-10-18 2006-11-29 Ucb Sa Biological products
US9512236B2 (en) 2006-12-19 2016-12-06 Ablynx N.V. Amino acid sequences directed against GPCRS and polypeptides comprising the same for the treatment of GPCR-related diseases and disorders
EP2102244A2 (de) 2006-12-19 2009-09-23 Ablynx N.V. Gegen metalloproteinase aus der adam-familie gerichtete aminosäuresequenzen und diese enthaltende polypeptide zur behandlung von mit adam in zusammenhang stehenden krankheiten und störungen
EP2557090A3 (de) 2006-12-19 2013-05-29 Ablynx N.V. Gegen GPCRs gerichtete Aminosäuresequenzen und Polypeptide damit zur Behandlung von Krankheiten und Störungen im Zusammenhang mit GPCR
US8404235B2 (en) 2007-05-21 2013-03-26 Alderbio Holdings Llc Antagonists of IL-6 to raise albumin and/or lower CRP
US8252286B2 (en) 2007-05-21 2012-08-28 Alderbio Holdings Llc Antagonists of IL-6 to prevent or treat thrombosis
US7906117B2 (en) 2007-05-21 2011-03-15 Alderbio Holdings Llc Antagonists of IL-6 to prevent or treat cachexia, weakness, fatigue, and/or fever
WO2008144753A2 (en) 2007-05-21 2008-11-27 Alder Biopharmaceuticals, Inc. Antibodies to tnf alpha and use thereof
US8062864B2 (en) 2007-05-21 2011-11-22 Alderbio Holdings Llc Nucleic acids encoding antibodies to IL-6, and recombinant production of anti-IL-6 antibodies
MX2009012492A (es) 2007-05-21 2010-01-20 Alder Biopharmaceuticals Inc Anticuerpos para il-6 y sus usos.
US8178101B2 (en) 2007-05-21 2012-05-15 Alderbio Holdings Inc. Use of anti-IL-6 antibodies having specific binding properties to treat cachexia
GB0717337D0 (en) 2007-09-06 2007-10-17 Ucb Pharma Sa Method of treatment
JP5592792B2 (ja) 2007-09-26 2014-09-17 ユセベ ファルマ ソシエテ アノニム 二重特異性抗体の融合体
WO2009068627A2 (en) 2007-11-27 2009-06-04 Ablynx N.V. Amino acid sequences directed against heterodimeric cytokines and/or their receptors and polypeptides comprising the same
WO2009072660A1 (ja) * 2007-12-03 2009-06-11 Kabushiki Kaisya Advance 抗体作製方法
WO2009082624A2 (en) * 2007-12-10 2009-07-02 Zymogenetics, Inc. Antagonists of il-17a, il-17f, and il-23 and methods of using the same
GB0800277D0 (en) 2008-01-08 2008-02-13 Imagination Tech Ltd Video motion compensation
EP2098536A1 (de) 2008-03-05 2009-09-09 4-Antibody AG Isolation und Identifikation antigen- oder ligandenspezifischer Bindungsproteine
EP2947097A1 (de) 2008-04-07 2015-11-25 Ablynx N.V. Gegen Notch-Signalwege gerichtete Aminosäuresequenzen und Verwendungen davon
GB0807413D0 (en) * 2008-04-23 2008-05-28 Ucb Pharma Sa Biological products
EP2285833B1 (de) 2008-05-16 2014-12-17 Ablynx N.V. Gegen cxcr4 und andere gpcr gerichtete aminosäuresequenzen sowie verbindungen damit
SI2285408T1 (sl) 2008-06-05 2019-02-28 Ablynx N.V. Aminokislinska zaporedja usmerjena proti proteinom ovojnicam virusa in polipeptidi, ki zaporedja vsebujejo za zdravljenje virusnih bolezni
US8992920B2 (en) 2008-11-25 2015-03-31 Alderbio Holdings Llc Anti-IL-6 antibodies for the treatment of arthritis
US8323649B2 (en) 2008-11-25 2012-12-04 Alderbio Holdings Llc Antibodies to IL-6 and use thereof
US9452227B2 (en) 2008-11-25 2016-09-27 Alderbio Holdings Llc Methods of treating or diagnosing conditions associated with elevated IL-6 using anti-IL-6 antibodies or fragments
US8337847B2 (en) 2008-11-25 2012-12-25 Alderbio Holdings Llc Methods of treating anemia using anti-IL-6 antibodies
US9212223B2 (en) 2008-11-25 2015-12-15 Alderbio Holdings Llc Antagonists of IL-6 to prevent or treat thrombosis
US8420089B2 (en) 2008-11-25 2013-04-16 Alderbio Holdings Llc Antagonists of IL-6 to raise albumin and/or lower CRP
CN107011434B (zh) 2008-12-19 2021-02-19 埃博灵克斯股份有限公司 用于产生针对细胞相关抗原如p2x7、cxcr7或cxcr4的免疫球蛋白的基因免疫
GB0900425D0 (en) 2009-01-12 2009-02-11 Ucb Pharma Sa Biological products
PE20120211A1 (es) 2009-02-17 2012-03-24 Ucb Pharma Sa Anticuerpos que tienen especificidad por ox40 humana
EP2401294B1 (de) 2009-02-25 2018-09-05 UCB Biopharma SPRL Verfahren zur herstellung von antikörpern
GB0903207D0 (en) 2009-02-25 2009-04-08 Ucb Pharma Sa Method for expressing multimeric proteins
GB0904214D0 (en) 2009-03-11 2009-04-22 Ucb Pharma Sa Biological products
WO2010129541A1 (en) * 2009-05-04 2010-11-11 Affomix Corporation Emulsion selection of antibodies
GB201005063D0 (en) 2010-03-25 2010-05-12 Ucb Pharma Sa Biological products
CA2778673A1 (en) 2009-10-27 2011-05-05 Karen Margrete Miller Function modifying nav 1.7 antibodies
US9234037B2 (en) 2009-10-27 2016-01-12 Ucb Biopharma Sprl Method to generate antibodies to ion channels
GB0922435D0 (en) 2009-12-22 2010-02-03 Ucb Pharma Sa Method
GB0922434D0 (en) 2009-12-22 2010-02-03 Ucb Pharma Sa antibodies and fragments thereof
JP5934652B2 (ja) 2009-11-24 2016-06-15 アルダーバイオ ホールディングス エルエルシー Ｉｌ−６に対する抗体およびその使用
US9775921B2 (en) 2009-11-24 2017-10-03 Alderbio Holdings Llc Subcutaneously administrable composition containing anti-IL-6 antibody
EP2506874A1 (de) 2009-12-01 2012-10-10 Ablynx N.V. Von-willebrand-faktor-spezifische bindemittel und ihre verwendung
WO2011073180A1 (en) 2009-12-14 2011-06-23 Ablynx N.V. Single variable domain antibodies against ox40l, constructs and therapeutic use
US9120855B2 (en) 2010-02-10 2015-09-01 Novartis Ag Biologic compounds directed against death receptor 5
CA2791930A1 (en) 2010-03-11 2011-09-15 Kerry Louise Tyson Pd-1 antibody
TW201134488A (en) 2010-03-11 2011-10-16 Ucb Pharma Sa PD-1 antibodies
GB201005064D0 (en) 2010-03-25 2010-05-12 Ucb Pharma Sa Biological products
WO2011117653A1 (en) 2010-03-25 2011-09-29 Ucb Pharma S.A. Disulfide stabilized dvd-lg molecules
US8937164B2 (en) 2010-03-26 2015-01-20 Ablynx N.V. Biological materials related to CXCR7
TWI667346B (zh) 2010-03-30 2019-08-01 中外製藥股份有限公司 促進抗原消失之具有經修飾的FcRn親和力之抗體
EP2571901B1 (de) 2010-05-20 2019-01-02 Ablynx N.V. Biologische stoffe im zusammenhang mit her3
GB201014033D0 (en) 2010-08-20 2010-10-06 Ucb Pharma Sa Biological products
TWI619730B (zh) 2010-11-08 2018-04-01 Ablynx Nv 趨化細胞素受體結合多肽
WO2012071554A2 (en) 2010-11-23 2012-05-31 Alder Biopharmaceuticals, Inc. Anti-il-6 antibodies for the treatment of oral mucositis
WO2012095662A1 (en) 2011-01-14 2012-07-19 Ucb Pharma S.A. Antibody molecules which bind il-17a and il-17f
EP2691418A1 (de) 2011-03-28 2014-02-05 Ablynx N.V. Bispezifische gegen cxcr4 gerichtete variable immglobulineinzeldomänen
UA117218C2 (uk) 2011-05-05 2018-07-10 Мерк Патент Гмбх Поліпептид, спрямований проти il-17a, il-17f та/або il17-a/f
EP3363813A1 (de) 2011-06-23 2018-08-22 Ablynx NV Verfahren für vorhersage, nachweis und verringerung von aspezifischer proteininterferenz bei tests mit variablen immunglobulin-einzeldomänen
SG194982A1 (en) 2011-06-23 2013-12-30 Ablynx Nv Techniques for predicting, detecting and reducing aspecific protein interference in assays involving immunoglobulin single variable domains
DK2974737T3 (da) 2011-06-23 2026-01-19 Ablynx Nv Fremgangsmåder til forudsigelse, påvisning og reduktion af en specifik proteininterferens i assays, der involverer variable immunglobulin-enkeltdomæner
WO2013034579A1 (en) 2011-09-05 2013-03-14 Rheinische Friedrich-Wilhelms-Universität Bonn Biosynthetic gene cluster for the production of peptide/protein analogues
PL2758432T3 (pl) 2011-09-16 2019-08-30 Ucb Biopharma Sprl Przeciwciała neutralizujące przeciw głównym egzotoksynom tcda i tcdb z clostridium difficile
JP6411214B2 (ja) 2011-11-11 2018-10-24 ユーシービー バイオファルマ エスピーアールエル アルブミン結合抗体及びその結合断片
GB201201332D0 (en) 2012-01-26 2012-03-14 Imp Innovations Ltd Method
GB201203071D0 (en) 2012-02-22 2012-04-04 Ucb Pharma Sa Biological products
GB201203051D0 (en) 2012-02-22 2012-04-04 Ucb Pharma Sa Biological products
FR2987627B1 (fr) 2012-03-05 2016-03-18 Splicos Utilisation de rbm39 comme biomarqueur
US9328174B2 (en) 2012-05-09 2016-05-03 Novartis Ag Chemokine receptor binding polypeptides
GB201208370D0 (en) 2012-05-14 2012-06-27 Ucb Pharma Sa Antibodies
WO2014001557A1 (en) 2012-06-28 2014-01-03 Ucb Pharma S.A. A method for identifying compounds of therapeutic interest
EP2727942A1 (de) 2012-11-05 2014-05-07 MAB Discovery GmbH Bispezifische Antikörper gegen menschliche EGFR, HER2 und HER3
US20150259430A1 (en) 2012-11-05 2015-09-17 Mab Discovery Gmbh Method for the production of multispecific antibodies
EP2727943A1 (de) 2012-11-05 2014-05-07 MAB Discovery GmbH Trispezifische Antikörper gegen menschliche EGFR, HER2 und HER3
EP2727941A1 (de) 2012-11-05 2014-05-07 MAB Discovery GmbH Verfahren zur Herstellung multispezifischer Antikörper
GB201223276D0 (en) 2012-12-21 2013-02-06 Ucb Pharma Sa Antibodies and methods of producing same
GB201315487D0 (en) 2013-08-30 2013-10-16 Ucb Pharma Sa Antibodies
SI3021859T1 (en) 2013-10-25 2018-04-30 Psioxus Therapeutics Limited Oncolytic adenoviruses equipped with heterologous genes
GB201320066D0 (en) 2013-11-13 2013-12-25 Ucb Pharma Sa Biological products
US9045545B1 (en) 2014-07-15 2015-06-02 Kymab Limited Precision medicine by targeting PD-L1 variants for treatment of cancer
US9067998B1 (en) 2014-07-15 2015-06-30 Kymab Limited Targeting PD-1 variants for treatment of cancer
US8986694B1 (en) 2014-07-15 2015-03-24 Kymab Limited Targeting human nav1.7 variants for treatment of pain
US8992927B1 (en) 2014-07-15 2015-03-31 Kymab Limited Targeting human NAV1.7 variants for treatment of pain
US9914769B2 (en) 2014-07-15 2018-03-13 Kymab Limited Precision medicine for cholesterol treatment
GB201403775D0 (en) 2014-03-04 2014-04-16 Kymab Ltd Antibodies, uses & methods
GB201406608D0 (en) 2014-04-12 2014-05-28 Psioxus Therapeutics Ltd Virus
GB201409558D0 (en) 2014-05-29 2014-07-16 Ucb Biopharma Sprl Method
GB201411320D0 (en) 2014-06-25 2014-08-06 Ucb Biopharma Sprl Antibody construct
US9139648B1 (en) 2014-07-15 2015-09-22 Kymab Limited Precision medicine by targeting human NAV1.9 variants for treatment of pain
GB201412659D0 (en) 2014-07-16 2014-08-27 Ucb Biopharma Sprl Molecules
GB201412658D0 (en) 2014-07-16 2014-08-27 Ucb Biopharma Sprl Molecules
EP3271393A4 (de) 2015-03-18 2018-10-31 Epitomics, Inc. Erzeugung monoklonaler antikörper mit hohem durchsatz zur b-zell-panning- und -proliferation
GB201506870D0 (en) 2015-04-22 2015-06-03 Ucb Biopharma Sprl Method
GB201506869D0 (en) 2015-04-22 2015-06-03 Ucb Biopharma Sprl Method
EP3288584A2 (de) 2015-04-30 2018-03-07 President and Fellows of Harvard College Anti-ap2-antikörper und antigenbindemittel zur behandlung von stoffwechselerkrankungen
GB201508180D0 (en) 2015-05-13 2015-06-24 Ucb Biopharma Sprl Antibodies
EP3303390A1 (de) 2015-05-27 2018-04-11 UCB Biopharma SPRL Verfahren zur behandlung neurologischer erkrankungen
GB201510758D0 (en) 2015-06-18 2015-08-05 Ucb Biopharma Sprl Novel TNFa structure for use in therapy
CN115505042A (zh) 2015-06-26 2022-12-23 赛诺菲生物技术公司 单克隆抗il-1racp抗体
GB201601077D0 (en) 2016-01-20 2016-03-02 Ucb Biopharma Sprl Antibody molecule
GB201601073D0 (en) 2016-01-20 2016-03-02 Ucb Biopharma Sprl Antibodies
GB201601075D0 (en) 2016-01-20 2016-03-02 Ucb Biopharma Sprl Antibodies molecules
SI3356398T1 (sl) 2015-09-30 2023-09-29 Icosagen Cell Factory Oue Postopek za razvijanje monoklonskih protiteles
KR20240156437A (ko) 2015-10-27 2024-10-29 유씨비 바이오파마 에스알엘 항-il-17a/f 항체를 사용한 치료 방법
GB201521382D0 (en) 2015-12-03 2016-01-20 Ucb Biopharma Sprl Antibodies
GB201521383D0 (en) 2015-12-03 2016-01-20 Ucb Biopharma Sprl And Ucb Celltech Method
GB201521391D0 (en) 2015-12-03 2016-01-20 Ucb Biopharma Sprl Antibodies
GB201521393D0 (en) 2015-12-03 2016-01-20 Ucb Biopharma Sprl Antibodies
GB201521389D0 (en) 2015-12-03 2016-01-20 Ucb Biopharma Sprl Method
GB201522394D0 (en) 2015-12-18 2016-02-03 Ucb Biopharma Sprl Antibodies
GB201602413D0 (en) 2016-02-10 2016-03-23 Nascient Ltd Method
EP3241845A1 (de) 2016-05-06 2017-11-08 MAB Discovery GmbH Humanisierte anti-il-1r3-antikörper
GB201610198D0 (en) 2016-06-10 2016-07-27 Ucb Biopharma Sprl Anti-ige antibodies
KR102379464B1 (ko) 2016-06-20 2022-03-29 키맵 리미티드 항-pd-l1 항체
SG10201913858WA (en) 2016-08-26 2020-03-30 Agency Science Tech & Res Macrophage stimulating protein receptor (or ron - recepteur d' origine nantais) antibodies and uses thereof
GB201616596D0 (en) 2016-09-29 2016-11-16 Nascient Limited Epitope and antibodies
EP3534947A1 (de) 2016-11-03 2019-09-11 Kymab Limited Antikörper, kombinationen mit antikörpern, biomarker, verwendungen und verfahren
GB201621635D0 (en) 2016-12-19 2017-02-01 Ucb Biopharma Sprl Crystal structure
EP4467565A3 (de) 2016-12-21 2025-03-12 Amgen Inc. Anti-tnf-alpha-antikörperformulierungen
EP3401332A1 (de) 2017-05-08 2018-11-14 MAB Discovery GmbH Anti-il-1r3 antikörper zur verwendung bei entzündungskrankheiten
GB201802486D0 (en) 2018-02-15 2018-04-04 Ucb Biopharma Sprl Methods
JP7565219B2 (ja) 2018-06-18 2024-10-10 ユーシービー バイオファルマ エスアールエル がんを予防及び治療するためのｇｒｅｍｌｉｎ－１アンタゴニスト
AR117653A1 (es) 2018-10-16 2021-08-25 UCB Biopharma SRL Método para tratamiento de miastenia grave
GB201817309D0 (en) 2018-10-24 2018-12-05 Ucb Biopharma Sprl Antibodies
GB201817311D0 (en) 2018-10-24 2018-12-05 Ucb Biopharma Sprl Antibodies
PE20211867A1 (es) 2018-11-01 2021-09-21 Shandong New Time Pharmaceutical Co Ltd Anticuerpos biespecificos y su uso
GB201900732D0 (en) 2019-01-18 2019-03-06 Ucb Biopharma Sprl Antibodies
GB201917480D0 (en) 2019-11-29 2020-01-15 Univ Oxford Innovation Ltd Antibodies
GB201919061D0 (en) 2019-12-20 2020-02-05 Ucb Biopharma Sprl Multi-specific antibody
GB201919058D0 (en) 2019-12-20 2020-02-05 Ucb Biopharma Sprl Multi-specific antibodies
GB201919062D0 (en) 2019-12-20 2020-02-05 Ucb Biopharma Sprl Antibody
GB202001447D0 (en) 2020-02-03 2020-03-18 Ucb Biopharma Sprl Antibodies
WO2021160269A1 (en) 2020-02-13 2021-08-19 UCB Biopharma SRL Anti cd44-ctla4 bispecific antibodies
ES2975410T3 (es) 2020-02-13 2024-07-05 UCB Biopharma SRL Anticuerpos biespecíficos que se unen a HVEM y CD9
WO2021160267A1 (en) 2020-02-13 2021-08-19 UCB Biopharma SRL Bispecific antibodies against cd9 and cd7
EP4103608A1 (de) 2020-02-13 2022-12-21 UCB Biopharma SRL Bispezifische antikörper gegen cd9 und cd137
WO2021160268A1 (en) 2020-02-13 2021-08-19 UCB Biopharma SRL Bispecific antibodies against cd9
AU2021361083A1 (en) 2020-10-13 2023-05-11 Almirall, S.A. Bispecific molecules and methods of treatment using the same
IL301859A (en) 2020-10-15 2023-06-01 UCB Biopharma SRL Binding molecules that multimerise cd45
CA3197465A1 (en) 2020-11-02 2022-05-05 UCB Biopharma SRL Use of anti-trem1 neutralizing antibodies for the treatment of motor neuron neurodegenerative disorders
MX2023006650A (es) 2020-12-07 2023-06-21 UCB Biopharma SRL Anticuerpos multiespecificos y combinaciones de anticuerpos.
CN116802211A (zh) 2020-12-07 2023-09-22 Ucb生物制药有限责任公司 针对白介素-22的抗体
US20240228593A9 (en) 2021-02-19 2024-07-11 The United States Of America, As Represented By The Secretary, Department Of Health & Human Services SINGLE DOMAIN ANTIBODIES THAT NEUTRALIZE SARS-CoV-2
US12467094B2 (en) 2021-03-11 2025-11-11 IgGenix, Inc. Methods and systems for predicting allergic response
EP4067381A1 (de) 2021-04-01 2022-10-05 Julius-Maximilians-Universität Würzburg Neue tnfr2-bindende moleküle
US20250277023A1 (en) 2021-04-22 2025-09-04 Guangdong Fapon Biopharma Inc. Multifunctional bispecific fusion polypeptide
IL308100A (en) 2021-05-03 2023-12-01 UCB Biopharma SRL Antibodies
WO2023285878A1 (en) 2021-07-13 2023-01-19 Aviation-Ophthalmology Methods for detecting, treating, and preventing gpr68-mediated ocular diseases, disorders, and conditions
GB202111905D0 (en) 2021-08-19 2021-10-06 UCB Biopharma SRL Antibodies
GB202205203D0 (en) 2022-04-08 2022-05-25 UCB Biopharma SRL Combination with inhibitor
GB202205200D0 (en) 2022-04-08 2022-05-25 Ucb Biopharma Sprl Combination with chemotherapy
WO2024050354A1 (en) 2022-08-31 2024-03-07 Washington University Alphavirus antigen binding antibodies and uses thereof
KR20250060305A (ko) 2022-09-21 2025-05-07 사노피 바이오테크놀로지 인간화 항-il-1r3 항체 및 사용 방법
WO2024083843A1 (en) 2022-10-18 2024-04-25 Confo Therapeutics N.V. Amino acid sequences directed against the melanocortin 4 receptor and polypeptides comprising the same for the treatment of mc4r-related diseases and disorders
JP2025539866A (ja) 2022-11-28 2025-12-09 ユーシービー バイオファルマ エスアールエル 線維筋痛症の処置
WO2025101487A1 (en) * 2023-11-06 2025-05-15 Bruker Cellular Analysis, Inc. Affinity assay for microfluidic devices
GB202318820D0 (en) 2023-12-08 2024-01-24 UCB Biopharma SRL Antibodies
TW202540204A (zh) 2024-01-26 2025-10-16 西班牙商阿爾米雷爾有限公司 雙特異性分子及使用其的治療方法
TW202547865A (zh) 2024-05-17 2025-12-16 比利時商Ｕｃｂ生物製藥公司 具有il-11結合特異性的抗體
WO2025238133A1 (en) 2024-05-17 2025-11-20 UCB Biopharma SRL Multispecific antibody with binding specificity for il-11 and il-17
WO2026027660A1 (en) 2024-08-02 2026-02-05 UCB Biopharma SRL Formulations of anti-gremlin-1 antibodies

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8308235D0 (en) 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
GB8928874D0 (en) 1989-12-21 1990-02-28 Celltech Ltd Humanised antibodies
WO1992002551A1 (en) 1990-08-02 1992-02-20 B.R. Centre Limited Methods for the production of proteins with a desired function
DE69126281T2 (de) * 1990-11-26 1997-10-16 Akzo Nobel Nv Verfahren zur Herstellung von Antikörpern
GB9718911D0 (en) * 1997-09-05 1997-11-12 Orion Yhtymae Oy Monoclonal antibodies
US20050147609A1 (en) * 1998-05-15 2005-07-07 Genentech, Inc. Use of anti-IL-17 antibody for the treatment of cartilage damaged by osteoarthritis
IL144578A0 (en) * 1999-01-29 2002-05-23 Imclone Systems Inc Antibodies specific to kdr and uses thereof
US6541225B1 (en) 2000-01-26 2003-04-01 Raven Biotechnologies, Inc. Methods and compositions for generating human monoclonal antibodies
GB0210121D0 (en) 2002-05-02 2002-06-12 Celltech R&D Ltd Biological products

Also Published As

Publication number Publication date
WO2004106377A1 (en) 2004-12-09
AU2004242823A1 (en) 2004-12-09
GB0312481D0 (en) 2003-07-09
DE602004025805D1 (de) 2010-04-15
US7790414B2 (en) 2010-09-07
JP2007535485A (ja) 2007-12-06
JP4624357B2 (ja) 2011-02-02
EP1633787B1 (de) 2010-03-03
ES2341544T3 (es) 2010-06-22
CA2526546A1 (en) 2004-12-09
EP1633787A1 (de) 2006-03-15
US20070009959A1 (en) 2007-01-11

Similar Documents

Publication Publication Date Title
ATE459652T1 (de) Verfahren zur herstellung von antikörpern
ATE554390T1 (de) Verfahren zur gewinnung von antikörpern
ATE468390T1 (de) System und verfahren zur produktion von antikörpern in der pflanzenzellkultur
DE60219321D1 (de) Einzelketten vhh antikörper aus kamelen, verfahren zur deren herstellung in einem saugetier und deren verwendungen
ATE513905T1 (de) Verfahren für die replikation von influenza in zellkultur, und die bei diesem verfahren hergestellten influenza viren
ATE556091T2 (de) Monoklonale antikörperproduktion durch ebv transformation von b-zellen
EA200800996A1 (ru) Способ получения т-клеточной популяции
IL165390A0 (en) Methods for identifying and extracting endotoxin
WO2006127809A3 (en) Methods for expansion and analysis of cultured hematopoietic stem cells
DE60314898D1 (de) Zusammensetzungen und verfahren zur trennung von zellen
ATE479743T1 (de) Verfahren zur herstellung von zellkulturen aus biologischen präparaten für chemotherapeutische und andere assays
ATE279441T1 (de) Verfahren zur herstellung von genetisch veränderten lymphozyten vorläuferzellen von wirbeltieren und deren gebrauch zur produktion von heterologen bindeproteinen
DE60319599D1 (de) Verfahren zur differenzierung einer mesenchym-stammzelle zu einer nervenzelle sowie die nervenzelle eine neurodegenerative krankheit
ATE469917T2 (de) Verfahren zur gewinnung von antikörpern
EP1645183A4 (de) Verfahren zur herstellung von immunkompetenten zellen menschlichen ursprungs
WO2001079541A3 (en) Improvements in and relating to analysis of dna samples
ATE505535T1 (de) Verfahren zur herstellung stabiler b-lymphozyten
IL164625A (en) Method for producing a plurality of monoclonal antibodies and method for identifying a plurality of monoclonal antibodies
DE50107753D1 (de) Verfahren zur abtrennung von lebensfähigen säuger- oder insekten-zellen aus zellsuspensionen
WO2009102697A3 (en) Methods of obtaining antigen-specific t cell populations
DE602005000249D1 (de) Verfahren zur Isolierung von Bakterien aus biologischen Proben
ATE405592T1 (de) Verfahren zur bildung eines protein- mikroarraysystems
DE69934250D1 (de) Zusammensetzungen und verfahren zur herstellung monoklonaler antikörper, repräsentativ für einen spezifischen zelltyp
DE50307968D1 (de) Antikörper zur isolierung und/oder identifizierung mesenchymaler stammzellen und verfahren zur isolierung und/oder identifizierung mesenchymaler stammzellen
DE602004029578D1 (de) Verfahren zur immuntherapie von tumoren

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties